Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Receivables (2016 - 2022)

Historic Receivables for Summit Therapeutics (SMMT) over the last 5 years, with Q4 2022 value amounting to $349000.0.

  • Summit Therapeutics' Receivables fell 8287.54% to $349000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $349000.0, marking a year-over-year decrease of 8287.54%. This contributed to the annual value of $349000.0 for FY2022, which is 8287.54% down from last year.
  • As of Q4 2022, Summit Therapeutics' Receivables stood at $349000.0, which was down 8287.54% from $140000.0 recorded in Q3 2022.
  • Over the past 5 years, Summit Therapeutics' Receivables peaked at $22.2 million during Q1 2019, and registered a low of $140000.0 during Q3 2022.
  • Moreover, its 4-year median value for Receivables was $2.2 million (2021), whereas its average is $6.0 million.
  • Its Receivables has fluctuated over the past 5 years, first crashed by 9714.62% in 2020, then skyrocketed by 51571.0% in 2021.
  • Summit Therapeutics' Receivables (Quarter) stood at $11.6 million in 2019, then tumbled by 97.15% to $331000.0 in 2020, then skyrocketed by 515.71% to $2.0 million in 2021, then tumbled by 82.88% to $349000.0 in 2022.
  • Its Receivables was $349000.0 in Q4 2022, compared to $140000.0 in Q3 2022 and $1.3 million in Q2 2022.